MARC Record from marc_columbia

LEADER: 02117cam a2200349 i 4500
001 9046184
005 20111122002456.0
008 110203t20112011ilua b 001 0 eng c
010 $a 2011004666
020 $a9780226359182 (cloth : alkaline paper)
020 $a0226359182 (cloth : alkaline paper)
024 $a40019894144
035 $a(OCoLC)701242603
035 $a(OCoLC)ocn701242603
035 $a(NNC)9046184
040 $aICU/DLC$cDLC$dYDX$dYDXCP
042 $apcc
043 $an-us---
050 00 $aHD9999.B444$bH85 2011
082 00 $a338.7/66060973$222
100 1 $aHughes, Sally Smith.
245 10 $aGenentech :$bthe beginnings of biotech /$cSally Smith Hughes.
260 $aChicago :$bUniversity of Chicago Press,$c2011, ©2011.
300 $axv, 213 p. :$bill. ;$c24 cm.
490 1 $aSynthesis
504 $aIncludes bibliographical references and index.
505 0 $a1. Inventing recombinant DNA technology ; Scientists on converging paths ;The collaboration ; Patenting and politics ; Steps toward commercialization -- 2. Creating Genentech ; Bob Swanson ; Founding Genentech ; Legal and political obstacles ; A full business plan -- 3. Proving the technology ; A portentous experiment ; Switching targets ; Negotiating research agreements -- Making somatostatin ; Wider issues -- 4. Human insulin: Genentech makes its mark ; Seeking corporate contracts; Procuring a facility and staff ; Genentech's human insulin project ; The Eli Lilly contract ; Publicity and expansion -- 5. Human growth hormone: shaping a commercial future ; Competing for human growth hormone ; Moving toward corporate integration ; Scaling up insulin and growth hormone ; Corporate expansion ; An emerging culture -- 6. Wall Street debut ; Biomania ; Exit strategies ; Interferon: the new wonder drug? ; Run-up to an initial public offering ; Legal impediments ; The IPO.
610 20 $aGenentech, Inc.$xHistory.
650 0 $aBiotechnology industries$zUnited States$xHistory.
650 0 $aBiotechnology$xHistory.
830 0 $aSynthesis (University of Chicago. Press)
852 00 $boff,bus$hHD9999.B444$iH85 2011